Core Viewpoint - Cocrystal Pharma has initiated a Phase 1b clinical trial for CDI-988, an oral antiviral aimed at preventing and treating norovirus infections, addressing a significant global health need [1][2][3] Group 1: Clinical Study Details - The Phase 1b study is randomized, double-blind, and placebo-controlled, enrolling up to 40 healthy subjects aged 18-49, all of whom will be infected with the GII.2 norovirus strain [2][7] - The primary endpoint of the study is to evaluate the efficacy of CDI-988 compared to placebo in reducing clinical symptoms, with secondary endpoints including viral shedding, disease severity, safety, and pharmacokinetics [7] Group 2: Drug Development and Technology - CDI-988 is the first direct-acting oral antiviral developed specifically for norovirus, targeting a conserved region of the viral 3CL protease found in all known norovirus strains [1][6] - Cocrystal's proprietary structure-based drug discovery platform enables the development of novel antiviral agents by providing detailed structural insights for drug design [5][9] Group 3: Norovirus Impact - Norovirus causes an estimated 685 million cases globally each year, with a significant economic impact of $60 billion, highlighting the urgent need for effective treatments [4][6] - In the U.S., norovirus is responsible for approximately 21 million infections annually, leading to substantial healthcare costs and hospitalizations [4]